文献速递前列腺癌

阴性PSMA PET可用于避免中危前列腺癌中不必要的盆腔淋巴结清扫

Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-01-06

该研究基于高容量中心2016至2021年数据库,纳入371例Grade Group 2-3且PSA≤20 ng/ml、根治性前列腺切除术前PSMA PET阴性的中危前列腺癌患者,比较行与未行盆腔淋巴结清扫者的无生化复发生存。结果显示36个月无生化复发生存率两组无显著差异,PSMA PET对淋巴结侵犯的阴性预测值为90.1%,作者认为PSMA PET阴性时可避免盆腔淋巴结清扫。

要点

  • PSMA PET对淋巴结侵犯的阴性预测值为90.1%。
  • 36个月无生化复发生存率清扫组78.7% vs 未清扫组76.7%(p=0.8),无显著差异。
  • 主要局限性为缺乏长期肿瘤学结局。

核心结论

  • 在中危前列腺癌患者中,PSMA PET阴性时可避免行盆腔淋巴结清扫。

研究设计与样本

  • 在高容量中心数据库中识别2016至2021年间根治性前列腺切除术前PSMA PET阴性的Grade Group 2-3且PSA≤20 ng/ml患者,共371例。
  • 333例(90%)行根治性前列腺切除加盆腔淋巴结清扫,38例(10%)未行盆腔淋巴结清扫。
  • 采用Kaplan-Meier分析比较行与未行盆腔淋巴结清扫患者的无生化复发生存。

主要发现

  • 盆腔淋巴结清扫组切除淋巴结中位数为16枚。
  • PSMA PET检测淋巴结侵犯的阴性预测值为90.1%。
  • 中位随访36个月,术前PSA中位值7.8 ng/ml。
  • 穿刺Grade Group 2占59%,Grade Group 3占41%。
  • 前列腺切除术后36个月无生化复发生存率清扫组78.7% vs 未清扫组76.7%(p=0.8),无显著差异。

临床怎么用

  • 作者认为,中危前列腺癌患者PSMA PET阴性时,可避免行盆腔淋巴结清扫。

局限性

  • 主要局限性为缺乏长期肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has a high negative predictive value (NPV) in determining lymph node invasion (LNI) in men with intermediate-risk disease undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND). We hypothesized that PSMA PET may be used to reduce the number of unnecessary PLND procedures performed. OBJECTIVE: To assess BCR-free survival of intermediate risk prostate cancer patients with a negative PSMA PET who underwent PLND vs. no PLND. DESIGN, SETTING, AND PARTICIPANTS: Within a high-volume center database, we identified patients with Grade Group 2-3 and PSA ≤ 20 ng/ml who had a negative PSMA PET prior to RP between 2016 and 2021. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier analyses were used to compare BCR-free survival between patients with and without PLND. RESULTS AND LIMITATIONS: Overall, 371 patients were identified. Of those, 333 (90%) underwent RP with PLND, while 38 (10%) had no PLND during RP. Median number of removed lymph nodes in patients with PLND was 16. The NPV of PSMA PET for LNI detection was 90.1%. Median follow-up was 36 months. The median preoperative PSA was 7.8 ng/ml. 59% had biopsy Grade Group 2 and 41% had biopsy Grade Group 3, respectively. BCR-free survival at 36 months after prostatectomy was 78.7% vs. 76.7% (p = 0.8) for patients with vs. without PLND. Main limitation is the absence of long-term oncologic outcomes. CONCLUSIONS: In intermediate risk prostate cancer patients, a PLND may be avoided in the presence of a negative PSMA PET.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Incesu RB, Preisser F, Nohe F, et al. Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer. Prostate Cancer Prostatic Dis. 2025. PMID: 39762549. doi:10.1038/s41391-024-00930-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。